Forte Biosciences Inc (FBRX) - Net Assets
Based on the latest financial reports, Forte Biosciences Inc (FBRX) has net assets worth $84.10 Million USD as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($97.09 Million) and total liabilities ($12.99 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Forte Biosciences Inc tangible equity quality to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $84.10 Million |
| % of Total Assets | 86.62% |
| Annual Growth Rate | 3.33% |
| 5-Year Change | -11.02% |
| 10-Year Change | N/A |
| Growth Volatility | 396.02 |
Forte Biosciences Inc - Net Assets Trend (2015–2024)
This chart illustrates how Forte Biosciences Inc's net assets have evolved over time, based on quarterly financial data. See Forte Biosciences Inc defensive liquidity buffer to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Forte Biosciences Inc (2015–2024)
The table below shows the annual net assets of Forte Biosciences Inc from 2015 to 2024. For live valuation and market cap data, see Forte Biosciences Inc (FBRX) market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $52.48 Million | +48.61% |
| 2023-12-31 | $35.31 Million | -9.03% |
| 2022-12-31 | $38.82 Million | -6.57% |
| 2021-12-31 | $41.55 Million | -29.56% |
| 2020-12-31 | $58.98 Million | +926.45% |
| 2019-12-31 | $5.75 Million | -90.12% |
| 2018-12-31 | $58.15 Million | -18.20% |
| 2017-12-31 | $71.08 Million | +916.04% |
| 2016-12-31 | $7.00 Million | -82.10% |
| 2015-12-31 | $39.08 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Forte Biosciences Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 5948600000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $6.00K | 0.01% |
| Other Comprehensive Income | $11.00K | 0.02% |
| Other Components | $206.46 Million | 393.41% |
| Total Equity | $52.48 Million | 100.00% |
Forte Biosciences Inc Competitors by Market Cap
The table below lists competitors of Forte Biosciences Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Kangstem Biotech Co. Ltd
KQ:217730
|
$172.10 Million |
|
Toro Ltd
NASDAQ:TORO
|
$172.11 Million |
|
Group Eleven Resources Corp
V:ZNG
|
$172.11 Million |
|
Hyosung Chemical Corp
KO:298000
|
$172.11 Million |
|
Astral Resources NL
AU:AAR
|
$172.04 Million |
|
Iris Acquisition Corp II
NYSE:IRAB
|
$172.02 Million |
|
Bluerock Acquisition Corp. Class A Ordinary Shares
NASDAQ:BLRK
|
$171.98 Million |
|
ESAF Small Finance Bank
NSE:ESAFSFB
|
$171.93 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Forte Biosciences Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 35,314,000 to 52,480,000, a change of 17,166,000 (48.6%).
- Net loss of 35,478,000 reduced equity.
- Share repurchases of 1,000 reduced equity.
- New share issuances of 53,000,000 increased equity.
- Other comprehensive income increased equity by 7,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-35.48 Million | -67.6% |
| Share Repurchases | $1.00K | -0.0% |
| Share Issuances | $53.00 Million | +100.99% |
| Other Comprehensive Income | $7.00K | +0.01% |
| Other Changes | $-362.00K | -0.69% |
| Total Change | $- | 48.61% |
Book Value vs Market Value Analysis
This analysis compares Forte Biosciences Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.98x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has increased from 0.02x to 0.98x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2015-12-31 | $803.75 | $17.59 | x |
| 2016-12-31 | $132.66 | $17.59 | x |
| 2017-12-31 | $1824.81 | $17.59 | x |
| 2018-12-31 | $43.48 | $17.59 | x |
| 2019-12-31 | $68.14 | $17.59 | x |
| 2020-12-31 | $200.37 | $17.59 | x |
| 2021-12-31 | $74.36 | $17.59 | x |
| 2022-12-31 | $55.83 | $17.59 | x |
| 2023-12-31 | $27.96 | $17.59 | x |
| 2024-12-31 | $18.00 | $17.59 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Forte Biosciences Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -67.60%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.17x
- Recent ROE (-67.60%) is above the historical average (-107.08%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2015 | -58.99% | -45207.84% | 0.00x | 1.59x | $-26.96 Million |
| 2016 | -478.53% | -68322.45% | 0.00x | 5.05x | $-34.18 Million |
| 2017 | -54.77% | -94948.78% | 0.00x | 1.30x | $-46.04 Million |
| 2018 | -84.19% | -271.43% | 0.17x | 1.77x | $-54.77 Million |
| 2019 | -70.81% | -11302.78% | 0.00x | 1.33x | $-4.64 Million |
| 2020 | -78.82% | 0.00% | 0.00x | 1.04x | $-52.38 Million |
| 2021 | -52.25% | 0.00% | 0.00x | 1.04x | $-25.86 Million |
| 2022 | -35.71% | 0.00% | 0.00x | 1.08x | $-17.74 Million |
| 2023 | -89.13% | 0.00% | 0.00x | 1.10x | $-35.01 Million |
| 2024 | -67.60% | 0.00% | 0.00x | 1.17x | $-40.73 Million |
Industry Comparison
This section compares Forte Biosciences Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $155,285,360
- Average return on equity (ROE) among peers: -101.11%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Forte Biosciences Inc (FBRX) | $84.10 Million | -58.99% | 0.15x | $172.07 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-34.80 Million | 0.00% | 0.00x | $83.17 Million |
| Abcellera Biologics Inc (ABCL) | $830.51 Million | 14.32% | 0.21x | $1.61 Billion |
| Abeona Therapeutics Inc (ABEO) | $-26.99 Million | 0.00% | 0.00x | $321.39 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $155.29 Million |
| Abpro Holdings, Inc. (ABP) | $3.07 Million | -479.81% | 1.57x | $2.00 Million |
| Absci Corp (ABSI) | $179.13 Million | -57.56% | 0.19x | $1.01 Billion |
| Arbutus Biopharma Corp (ABUS) | $182.50 Million | -46.25% | 0.30x | $831.63 Million |
| ABVC Biopharma Inc (ABVC) | $4.59 Million | -357.76% | 1.38x | $35.10 Million |
| Abivax SA American Depositary Shares (ABVX) | $33.94 Million | -14.97% | 0.12x | $7.98 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $113.93 Million | -49.49% | 0.18x | $3.66 Billion |
About Forte Biosciences Inc
Forte Biosciences, Inc. operates as a clinical-stage biopharmaceutical company in the United States. The company's lead product candidate is the FB-102, a proprietary anti-CD122 monoclonal antibody therapeutic candidate for various autoimmune and autoimmune-related indications, such as graft-vs-host disease, vitiligo, and alopecia areata, as well as for celiac disease and non-segmental vitiligo. … Read more